

NOW ENROLLING IN MUSCLE-INVASIVE BLADDER CANCER




PHASE 3 (NCT04209114)

PIVOT IO 009: Bempegaldesleukin with nivolumab for the neoadjuvant and adjuvant treatment of resectable muscle-invasive bladder cancer

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy or standard of care for the neoadjuvant and adjuvant treatment of patients with cisplatin-ineligible resectable MIBC¹

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



Bempegaldesleukin is an investigational CD122-preferential IL-2-pathway agonist²

Nivolumab is a PD-1 blocking antibody³

BEMPEG, bempegaldesleukin (NKTR-214); ECOG PS, Eastern Cooperative Oncology Group performance status; MIBC, muscle-invasive bladder cancer; NIVO, nivolumab; PD-1, programmed death-1

1. ClinicalTrials.gov. NCT04209114. <https://clinicaltrials.gov/ct2/show/NCT04209114>. Accessed March 29, 2021; 2. Bentebibel SE, et al. *Cancer Discov* 2019;9:711-21;

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: January 2021).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



^aNeoadjuvant and adjuvant setting.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; R/R, relapsed/refractory

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2021. All rights reserved.